Benedict Financial Advisors Inc. Takes $35,000 Position in Gain Therapeutics, Inc. (NASDAQ:GANX)

Benedict Financial Advisors Inc. bought a new position in shares of Gain Therapeutics, Inc. (NASDAQ:GANX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 16,000 shares of the company’s stock, valued at approximately $35,000.

Separately, Renaissance Technologies LLC increased its stake in shares of Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares during the last quarter. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Monday, November 25th. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Roth Mkm reissued a “buy” rating and issued a $7.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gain Therapeutics has an average rating of “Buy” and an average target price of $7.25.

Gain Therapeutics Stock Down 1.1 %

Shares of NASDAQ GANX opened at $2.61 on Friday. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The stock’s fifty day moving average price is $2.03 and its two-hundred day moving average price is $1.80. Gain Therapeutics, Inc. has a one year low of $0.89 and a one year high of $5.30.

Gain Therapeutics Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.